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Edited by Varda RotterAbstract We have established a spontaneously immortalized
chicken embryo ﬁbroblast (CEF) cell line (SC-1) that has been
in continuous culture for more than three years. This is only
the second report of a spontaneously immortalized reverse trans-
criptase (RT)-negative chicken cell line. The SC-1 cells emerged
from crisis (at about passage 29–31) with a slower growth rate
than primary cells. Passage 50 SC-1 cells expressed similar lev-
els of p53 mRNA, but slightly lower levels of p53 protein than
passage 6 CEF cells. By passage 120, p53 mRNA levels were sig-
niﬁcantly decreased in the SC-1 cells, while protein levels were
slightly increased compared to passage 6 CEF cells. However,
functional analysis of p53 revealed reduced activity in later pas-
sage SC-1 cells. Other p53-related genes including p21WAF1,
p27Kip1, MDM-2, and the p16INK4a alternate reading frame
(ARF) sequence showed similar patterns of diﬀerential mRNA
expression. Levels of p15INK4b mRNA and protein were dramat-
ically decreased in SC-1 cells, suggesting that the Rb pathway
also has been compromised. Telomerase expression was unde-
tectable in SC-1 cells. Fluorescence-activated cell sorting analy-
sis showed that SC-1 and primary cells contained a similar
proportion of G0/G1 phase cells, unlike the only other spontane-
ously immortalized chicken cell line (DF-1). The present study
suggests that alterations in the p53 and Rb pathways cause ﬂuc-
tuations in expression levels of important cell-cycle regulatory
genes during crucial transition periods as the SC-1 spontaneously
immortalized chicken ﬁbroblast cells progress toward becoming
a fully committed cell line.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Spontaneous immortalization1. Introduction
Spontaneous immortalization is a rare event in human and
avian cells, but occurs much more frequently in rodent cells
[1,2]. Most cells exhibit a limited replicative life-span resulting
in senescence. Normal cells propagated in vitro senesce after a
characteristic number of divisions [3]. With each cell division,
telomeres shorten due to the inability of DNA polymerases to
fully replicate the ends of linear chromosomes [4,5]. Evidence
indicates that telomere shortening acts as the mitotic clock*Corresponding author. Fax: +1 612 625 2743.
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critically shortened telomeres [6]. Somatic cell-cycle progres-
sion is tightly regulated. The tumor suppressors p53 and Rb
initiate pathways that result in cell-cycle arrest or cell death
when DNA damage is present [2,7]. Cellular immortalization
can be achieved by the loss of p53 and Rb and/or the activa-
tion of telomerase [2,8].
The tumor suppressor p53 is mutated or deleted in many
immortal and tumor cell lines with functional loss in greater
than 50% of all human tumors [9]. p53 is expressed ubiqui-
tously in all normal cells albeit with a very short half-life,
which is controlled by constant removal of newly synthesized
p53 via MDM-2 [10]. MDM-2 is the predominant negative
regulator of p53, and also is itself, a transcriptional target of
p53, whereby p53 drives the expression of its own negative reg-
ulator [11]. MDM-2 acts as an E3 ligase by ubiquitinating p53
for targeted nuclear export and degradation under normal
conditions. During normal growth, the short half-life of the
p53 protein does not allow it to initiate pathways that lead
to cell-cycle arrest or cell death. The half-life of p53 increases
in response to DNA damage via post-translational modiﬁca-
tions including phosphorylation and acetylation that prevent
subcellular redistribution and degradation by MDM-2 [12].
Upon activation, p53 can operate as both a transcriptional
activator and repressor. p53 increases the transcription of a
number of genes that are involved in cell-cycle arrest and
apoptosis, including p21WAF1 (which causes cell-cycle arrest
at both the G1 and G2 checkpoints) [13], Bax [14], PERP
[15], and Noxa [16], in addition to MDM-2. Alternatively,
p53 suppresses a variety of genes involved in cell growth and
tumorigenesis including c-Fos, c-Jun, Rb, and Bcl-2 [17].
Most immortal cell lines do not express p57Kip2 mRNA [18],
while overexpression of p57Kip2 arrests cells in the G1 phase of
the cell cycle [19]. Recent evidence suggests that p53 is neces-
sary for the expression of p57Kip2 [20]. In fact, the study by
Stampfer et al. [20] suggested that expression of p57Kip2 may
indicate that cells have not yet converted from a conditionally
immortal population of cells to a fully immortal cell line.
The Rb tumor suppressor pathway is, in part, controlled by
p16INK4a, which is an inhibitor of the cyclin-dependent kinases
(CDKs) 4 and 6 [21]. These CDKs work together with the D-
type cyclins to phosphorylate Rb. Hyperphosphorylated Rb
releases the transcription factor E2F-1, which is then free to
activate genes necessary for the S-phase of the cell cycle. At
senescence, levels of p16INK4a increase dramatically, resulting
in a hypophosphorylated Rb and G1 checkpoint arrestblished by Elsevier B.V. All rights reserved.
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p16INK4a. The genetic locus that encodes p16INK4a also en-
codes a structurally and functionally diﬀerent protein, the
p16INK4a alternate reading frame (ARF) sequence. Whereas
p16INK4a acts upstream of Rb, the ARF protein functions up-
stream of p53 by binding to MDM-2, preventing it from
degrading p53 [24,25]. Cellular levels of ARF increase progres-
sively as cells approach senescence [26]. In fact, ﬁbroblasts that
lack ARF proliferate indeﬁnitely, and ARF-deﬁcient mice are
more prone to develop tumors [27].
Numerous studies have shown that alterations in the p53 and
Rb pathways and the upregulation of telomerase are necessary
for immortalization [1]. In the present study the spontaneous
immortalization of a chicken embryo ﬁbroblast (CEF) cell line
(designated SC-1) is reported and used to study the inﬂuence of
various genes during the process of spontaneous immortaliza-
tion. This is the ﬁrst time that an analysis has been conducted
on a spontaneously immortalized cell line during the conver-
sion from a life-span-extended population of cells to a fully
immortal cell line. For technical reasons, an investigation of
this type was not possible for DF-1 cells – the only other reverse
transcriptase (RT)-negative spontaneously immortalized chick-
en cell line. Although a number of non-virally and non-chemi-
cally immortalized human and chicken cells have been
established in continuous culture, the availability of spontane-
ously immortalized cell lines allows for a unique opportunity to
study the naturally occurring changes that cells undergo as they
progress from a life-span-extended population of cells to a fully
immortal cell line. The spontaneously immortalized SC-1 cell
line has proved to be an ideal model with which to study the
importance of p53, since the expression of p53 ﬂuctuated as
the cells progressed to a fully immortalized cell line. Here we
determine if alterations in the p53 pathway have played a caus-
ative role in achieving full immortality in CEF cells.2. Materials and methods
2.1. Cells and culture conditions
Primary and immortal CEF cells were grown in DMEM high glu-
cose enriched with 10% fetal calf serum (FCS), 1% penicillin–strepto-
mycin, and 2 mM L-glutamine. All cell culture reagents were
purchased from Invitrogen (Carlsbad, CA). The spontaneously immor-
talized SC-1 CEF cell line was derived from SPAFAS eggs (speciﬁc
pathogen free avian supply, Charles River Laboratories, North Frank-
lin, CT). The spontaneously immortalized DF-1 CEF cell line was de-
rived from East Lansing Line 0 (ev-0) leghorn layer embryos (Avian
Disease and Oncology Laboratory, East Lansing, MI) [28,29].
2.2. Cell growth and cell-cycle analysis
To determine growth rates, primary (passages 6 and 18) and immor-
tal (DF-1 and SC-1) CEF cells were plated at a density of 3 · 105 cells/
10 cm dish using culture conditions as described above. At 80% conﬂu-
ency, cells were trypsinized, counted, and the number of population
doublings per day calculated. Cell growth also was determined by plat-
ing cells at a density of 1 · 105 cells/10 cm dish using conditions as de-
scribed above, and counting cells each day for up to 6 days to
determine cell numbers. Cell-cycle analysis was carried out using ﬂuo-
rescence-activated cell sorting (FACS) of propidium-iodide-stained
cells and a Cell Quest software program (Becton–Dickinson, Franklin
Lakes, NJ) as described [30].
2.3. Cell line characterization
Karyotypic analysis of cells was conducted by the Veterinary Diag-
nostic Laboratory at the University of Minnesota. The SC-1 cells were
analyzed twice for RT activity using the EnzCheck RT Assay kit(Molecular Probes/Invitrogen Inc., Eugene, OR) according to the man-
ufacturers instructions. Mycoplasma contamination was tested using
the Mycoplasma Plus kit (Stratagene, La Jolla, CA) according to
the manufacturers instructions.
2.4. RT-PCR analysis
For semi-quantitative RT-PCR, 3 lg of DNase I-treated RNA was
converted to cDNA using Superscript II reverse transcriptase (Invitro-
gen) following the manufacturers instructions. A portion (1 ll) of the
reverse transcription reaction was used to amplify cDNA fragments
with chicken-speciﬁc primers (information regarding primers and
PCR conditions used in RT-PCR will be provided upon request). All
semi-quantitative cDNA fragments were ampliﬁed using TaKaRa Ex
Taq (Intergen, Burlington, MA). PCR products were veriﬁed to be
in the linear range and visualized by ethidium bromide staining.
Images were processed using the Eagle Eye II still video system (Strat-
agene). To validate the above quantitation method, PCR products also
were ampliﬁed for 15 cycles (undetectable by ethidium bromide stain-
ing) and detected by standard Southern blot hybridization using their
corresponding [a-32P]-labeled cDNA probes prepared by RT-PCR
(data not shown). A minimum of three independent RT-PCR experi-
ments were analyzed using the NIH image software program and nor-
malized using the expression levels of GAPDH.
2.5. p53 and p15INK4b protein analyses
Cell lysate protein (30 lg; determined using the Bio-Rad protein re-
agent) was separated by SDS–PAGE with precast 4–20% gradient gels
(Bio-Rad, Hercules, CA). Gels were electro-transferred to nitrocellu-
lose membrane, and proteins were detected with antibodies speciﬁc
for p53 (SC-99, Santa Cruz Biotechnology, Santa Cruz, CA) and
p15INK4b (gift from Gordon Peters, London Research Institute, Lon-
don, UK), followed by horseradish peroxidase-labeled secondary anti-
body and either chemiluminescence or colorimetric detection systems.
2.6. p53 functional assay
A p53-Luciferase reporter plasmid was constructed in the pGL3
Luciferase reporter vector (Promega, Madison, WI) using double-
stranded oligonucleotides corresponding to tetramers of the p53 con-
sensus binding sequence (5 0-aggcatgcct-3 0) as described previously
[29]. Transient transfection was carried out using electroporation
(1100 lF, 275 V) as described previously [31]. For transfection, 20 lg
of promoter reporter plasmids (p53-Luc) or control reporter plasmids
(Con-Luc [29]) were cotransfected with 5 lg of pcDNA 3.1-LacZ plas-
mid. Transfection eﬃciency was normalized by ampliﬁcation of the
b-lactamase (LacZ) gene by PCR. Gel loading was normalized by
ampliﬁcation of the GAPDH gene by RT-PCR. Levels of luciferase
activity were determined using the Luciferase Assay System (Promega)
following the manufacturers instructions.
2.7. Inhibition of translation and transcription
Primary and immortal CEF cells were incubated in 10% FCS–
DMEM supplemented with either 10 lg/ml cycloheximide (CHX;
Sigma, St. Louis, MO) or 5 lg/ml actinomycin D (ActD; Sigma) for
various time points. All reagents described above were added into fresh
10% FCS–DMEM medium at the appropriate concentrations, then
used to refeed the cultures.
2.8. Silencing of p53
Short interfering RNA (siRNA) was designed to target p53 (sip53;
5 0-ggcgg aggagatgga accattgctg gaac-30). The p53 siRNA was ligated
to a U6 promoter and then cloned into the NruI and NotI sites of
the pcDNA3.1-Hygromycin vector (Invitrogen). Stable transfection
was carried out using electroportation (1100 lF, 275 V) as previously
described [31]. 20 lg of sip53-pcDNA3.1-Hygromycin (sip53) was
transfected into passage 58 SC-1 cells. Transfected cells were then se-
lected using Hygromycin B (50 lg/ml) for 10 days.3. Results and discussion
3.1. Growth rate and morphological analysis
In the present study a RT-negative spontaneously immor-
talized SC-1 cell line was established. Unlike DF-1 cells, the
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was gradual. Both the growth rate and morphological
changes experienced by the SC-1 cells indicated that they
were slowly progressing from a life-span-extended population
of cells into a fully established cell line. This is the ﬁrst anal-
ysis of important cell-cycle regulatory genes during the pro-
cess of spontaneous fully committed immortalization in
chicken cells.
Although data was obtained from many diﬀerent sequential
passages of SC-1 cells, only RT-PCR and protein data from
passages 50, 75, and 120 are shown, since they are representa-
tive of the major transition phases that occurred in the estab-
lishment of the SC-1 cells. The morphology of the SC-1 cells
was compared to presenescent (passage 6) and senescent (pas-
sage 18) primary CEF cells and to DF-1 cells – the only other
RT-negative spontaneously immortalized chicken cell line. Pas-
sage 18 CEF cells showed an enlarged, ﬂattened, and highly
vacuolated morphology, phenotypical of senescent ﬁbroblasts.
At Passage 50, SC-1 cells were ﬂattened and enlarged compared
to the presenescent primary passage 6 CEF cells, which dis-
played a spindle-shaped morphology, phenotypical of ﬁbro-
blasts. By passage 120, SC-1 cells appeared smaller than
passage 50 cells and possessed a more spindle-shaped morphol-
ogy, similar to passage 6 CEF cells. However, passage 120 SC-1
cells still appeared more elongated than DF-1 cells, which were
smaller and more uniform than presenescent passage 6 CEF
cells. When grown to conﬂuence, SC-1 cells displayed contact
inhibition and did not show evidence of multi-layered growth.
The SC-1 cells did not form foci when grown in a semi-solid
agarose suspension, suggesting that the cells do not possess
the properties of transformed cells (data not shown). Karyo-
typic analysis (data not shown) of the SC-1 cells indicated that
they displayed a normal diploid karyotype. The SC-1 cells were
analyzed twice for RT activity and mycoplasma contamination
and found to be negative for both (data not shown).
The growth curve for SC-1 CEF cells is shown in Fig. 1B.
Primary CEF cells were thawed at passage 5. Between passages
6 and 16, the growth rate of the CEF cells averaged 1.04 pop-Fig. 1. (A) Representative photomicrographs of primary CEF cells passage 6
SC-1 cells passage 120 (P120), and immortal passage 280 DF-1 cells. (B) Gr
cells/10 cm dish. At 80% conﬂuency cells were trypsinized, counted and theulation doublings per day (pd/d). Cells entered a crisis period
between passages 17 and 21. For the next few months there
was no detectable increase in cell number. During this period
cells were refed every 3–4 days and passaged every 10–15 days.
By passage 30, small foci of cells began to slowly divide and
increase their growth rates. The cells that emerged from this
crisis were considered to be potentially spontaneously immor-
tal and as such were designated as the SC-1 cell line. Cells be-
tween passages 31 and 51 were slow-growing, averaging only
0.18 pd/d, but doubled their growth rate between passages
52 and 94 (average of 0.35 pd/d). From passage 95 to 134,
SC-1 cells averaged 0.54 pd/d. Diﬀerent passages of SC-1 cells
were subjected to various growth media and serum concentra-
tions, and optimal growth was achieved using 10% fetal bovine
serum in high glucose DMEM. The SC-1 cell line now has been
in continuous culture for over three years and continues to in-
crease its growth rate, albeit slowly.
FACS analysis showed that SC-1 cells contained a similar
proportion of cells distributed throughout the cell cycle as
did primary CEF cells, with 60–70% of the cells in the G1
phase of the cell cycle (Fig. 2A). This is in contrast to the spon-
taneously immortalized DF-1 CEF cell line, which displayed
only 30% of the cells in the G1 phase of the cell cycle.
Cell growth rates were compared as shown in Fig. 2B. After
six days of growth passage 50 SC-1 cells displayed a very slow
growth rate of only 0.33 pd/d, while passage 120 SC-1 cells had
increased growth rates of 0.61 pd/d that were more similar to
primary passage 6 CEF cells at 0.72 pd/d, while DF-1 cells dis-
played the highest growth rate at 1.33 pd/d.
3.2. Analysis of p53 expression
We hypothesize that the SC-1 cell line has undergone one or
more transition periods in the process of stabilizing and con-
verting to a fully immortalized cell line, during which, expres-
sion levels of most of the cell-cycle regulatory genes have
ﬂuctuated. Since p53 plays such an important role in senes-
cence and tumor suppression, and is often deregulated in
life-span-extended cells, the mRNA expression levels of p53(P6), senescent CEF cells passage 18 (P18), SC-1 cells passage 50 (P50),
owth curve of SC-1 cells. SC-1 cells were plated at a density of 3 · 105
number of population doublings per day calculated.
Fig. 2. (A) Cell-cycle analysis of pre-senescent passage 6 CEF, passage 120 SC-1, and immortal passage 280 DF-1 cells was performed using FACS of
propidium-iodide-stained cells. (B) To determine growth rates, primary CEF (passage 6) and immortal CEF (passage 50 SC-1, passage 120 SC-1, and
passage 280 DF-1) cells were plated at a density of 1 · 105 cells/10 cm dish using conditions as described in Section 2. Both primary and immortal
CEF cells were counted each day for up to 6 days to determine cell numbers. The immortal DF-1 cells are only shown through day 4 due to their
relatively higher cell numbers.
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agreement with most other studies, an increased expression of
p53 mRNA in senescent passage 18 CEF cells compared to pri-
mary passage 6 CEF cells was observed (Fig. 3A). At passage
50, SC-1 cells displayed a p53 mRNA expression pattern sim-
ilar to levels found in passage 6 CEF cells and considerably
higher than displayed in DF-1 cells. But, at passages 75 and
120, SC-1 cells expressed very low levels of p53 mRNA (even
lower than the levels found in DF-1 cells; Fig. 3A).
This modulation in p53 mRNA levels suggests that the SC-1
cell line may be going through one or more transition or crisis
periods before becoming fully immortal. Other studies have
made reference to a process termed conversion, whereby
life-span-extended human mammary epithelial cells with no
telomerase activity and slow heterogenous growth, eventually
converted to a telomerase-expressing, uniform-growing, fully
immortal phenotype [20,32]. The conversion of these early-pas-
sage human mammary epithelial cells from a conditional- to
fully immortal phenotype extended over a 1–2 year in vitro
growth period [33]. Closer examination of the SC-1 cells after
life-span extension revealed that their growth characteristics
were more similar to that of primary CEF cells than to DF-1
spontaneously immortalized CEF cells. This indicated that
the SC-1 cell line may be a better representative of normal
CEF cell growth compared to the DF-1 line.To determine if the decreased p53 transcriptional activity in
SC-1 cells was caused by an inhibitory/repressor protein, cells
were treated with the protein synthesis inhibitor CHX, which
has been shown to stabilize several mRNAs [34]. It was previ-
ously shown that CHX treatment restored p53 mRNA levels in
CEF cells and in immortalized (10)3 and (10)7 murine embry-
onic ﬁbroblast cells expressing constitutively low levels of p53
mRNA [29]. In the present study, treatment of primary pas-
sage 6 CEF cells with CHX resulted in a modest increased
the expression of p53 mRNA, although in passage 120 SC-1
cells, treatment caused a 5-fold increase compared to untreated
cells (Fig. 3A). In fact, passage 120 SC-1 cells treated with
CHX restored the level of p53 to essentially the levels observed
in primary passage 6 CEF cells, suggesting that a p53 inhibi-
tory protein may have been present in the SC-1 cells that sup-
pressed expression of p53, allowing the SC-1 cells to overcome
the regulated constraints placed upon normal cells. The in-
creased p53 levels observed with CHX treatment was greater
than that expected from stabilization of mRNA due to CHX
alone, implying that a putative p53 inhibitory protein could
be responsible for the observed results.
The half-life of p53 mRNA in primary CEF and immortal
SC-1 cells was examined using the transcription inhibitor
ActD. To determine the destabilizing rates of p53 mRNA in
the CEF cells, primary CEF and immortal SC-1 cells were
Fig. 3. (A) Relative mRNA expression levels of p53 ± CHX treatment for 4 h. For analysis, the expression level was set to 1.00 for passage 6 CEF
cells. The expression levels for other samples were adjusted accordingly. A minimum of three independent RT-PCR experiments were analyzed using
the NIH image software program and normalized using the expression levels of GAPDH. Diﬀerences 60.05 were considered signiﬁcant. (B) p53
mRNA half-life in primary passage 6 CEF and immortal passage 120 SC-1 cells. To determine the half-life of p53 mRNA in immortal SC-1 cells,
CHX (20 lg/ml) pretreatment was ﬁrst performed. After 4 h, medium was removed and replaced with either normal or ActD containing medium.
Total RNA was isolated from primary and immortal SC-1 cells at the time-points indicated. The p53 mRNA levels were determined by semi-
quantitative RT-PCR. (C) p53 protein levels in primary passage 6 CEF, passage 50 SC-1 and passage 120 SC-1 cells. A minimum of three
independent Western blot experiments were analyzed using the NIH image software program and normalized using the expression levels of actin.
Diﬀerences 60.05 were considered signiﬁcant. (D) Altered biological activity of p53 in immortal SC-1 cells ± CHX using the luciferase reporter gene
assay. All cells were cotransfected with control reporter plasmid (Con-Luc) or p53 reporter plasmid (p53-Luc) and pcDNA3.1 LacZ plasmid. The b-
lactamase (LacZ) gene was ampliﬁed by PCR to normalize for transfection eﬃciency. Luciferase activity was determined using the Luciferase Assay
System (Promega) following manufacturers instructions. Luciferase activity in the cells transfected with the Con-Luc plasmid was set to 1.0. The
normalized values shown are relative expression levels with s.d. Diﬀerences 60.05 were considered signiﬁcant.
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lowing a CHX wash-out, primary and immortal CEF cells
were allowed to grow in either normal growth medium or
ActD-treated medium for diﬀerent times as indicated in
Fig. 3B. A relatively long 23-h half-life was observed for p53
mRNA in primary CEF cells (data not shown and [35]), with
the level of p53 mRNA remaining unchanged with or without
the addition of ActD following CHX pretreatment. How-
ever, the half-life of p53 mRNA in passage 120 SC-1 cells
was shortened to about 5.5 h (Fig. 3B).
Since the ability of p53 to activate or repress transcription of
downstream genes is important for cell-cycle control, theprotein level of p53 and direct functional activity also were
measured. Similar to the mRNA data that showed a ﬂuctua-
tion in the expression of p53 in SC-1 cells, a ﬂuctuation in
the protein level and functional activity of p53 in diﬀerent pas-
sages of SC-1 cells also was found. The level of p53 protein
slightly decreased in passage 50 SC-1 cells (but slightly in-
creased in passage 120 cells) when compared to primary pas-
sage 6 CEF cells (Fig. 3C). To determine whether the p53
protein was functional and not altered in the SC-1 cells, lucif-
erase activity was measured after transfection of a p53 consen-
sus binding sequence promoter/luciferase reporter plasmid
construct. The activity of p53 in the passage 120 SC-1 cells
Fig. 4. Relative mRNA expression levels of genes involved in the p53
pathway ± CHX treatment for 4 h. For analysis, the expression level
was set to 1.00 for passage 6 CEF cells. The expression levels for other
samples were adjusted accordingly. A minimum of three independent
RT-PCR experiments were analyzed using the NIH image software
program and normalized using the expression levels of GAPDH.
Diﬀerences 60.05 were considered signiﬁcant.
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CEF cells, and even less than that of the respective control re-
porter plasmid (Fig. 3D). This is in agreement with the p53
mRNA expression levels, and explains, in part, the ﬂuctuation
in the expression of genes that act downstream of p53 (MDM-
2, p21WAF1). Treatment with CHX resulted in no signiﬁcant
change in the functional activity of p53 in passage 120 SC-1
cells, suggesting that the increased mRNA resulting from
CHX treatment did not translate into functional protein. A
possible explanation for this discrepancy is the short half-life
of p53 mRNA detected in the SC-1 cells. The functional activ-
ity of p53 in passage 50 SC-1 cells was greater than the control
reporter plasmid (with CHX treatment resulting in a small in-
crease in activity), but was not as great as the activity found in
the primary passage 6 CEF cells.
Since diﬀerences in p53 transcriptional and functional activ-
ity were key to the ﬂuctuations observed in several important
cell-cycle regulatory genes, sequence analysis of p53 mRNA
was performed to determine whether DNA insertions, dele-
tions or substitutions may have been responsible for the al-
tered p53 activity in the SC-1 cells. The nucleotide sequence
of p53 in the SC-1 cells was identical to that of the published
chicken p53 mRNA sequence (Accession No. X13057) for
the ﬁrst portion of the 5 0-end and the remainder of the 3 0-
end (except for three base pair substitutions that did not result
in any amino acid substitutions). We have had diﬃculties in
sequencing the remaining approximate 250 bp (between nucle-
otides 242 and 494) that is predominantly double-stranded
[36]. With over 80% of the molecule sequenced, it appears that
there are no deletions or mutations that existed. These results
suggest that other cellular modiﬁcations may be responsible
for the altered activity of p53 in the SC-1 cells.
3.3. Expression of p53-related genes
To further verify that altered p53 expression is aﬀecting the
cell cycle, other p53-related genes were analyzed. An important
regulatory gene in the p53 pathway is MDM-2, a proto-onco-
gene that binds to p53, inactivating its transcriptional activity
[37,38]. When cells encounter genotoxic stresses (and in partic-
ular, DNA damage), p53 becomes post-translationally altered
via phosphorylation and acetylation [12], and the binding of
p53 to MDM-2 is prevented. However, p53 also regulates its
own activity by enhancing the expression of MDM-2 [39]. In
the present study, the levels of MDM-2 mRNA in the SC-1
cells were 30% lower at passage 50, 80% lower at passage 75,
and 30% lower at passage 120 compared to primary passage
6 CEF cells (similar to the lower level observed in the DF-1
cells; Fig. 4). The coordinate ﬂuctuation of MDM-2 and p53
mRNA indicates that the SC-1 cells were modulating the
expression of these cell-cycle regulatory genes in order to reach
homeostasis and a fully immortal state. Since CHX treatment
increased the expression of p53 in the passage 120 SC-1 cells,
the increase observed in MDM-2 expression with CHX treat-
ment was expected and supports the hypothesis that the in-
creased expression of p53 was not due to mRNA stability
via CHX, and could indicate the possible presence of a p53
repressor protein.
Taking a closer look at the p53 pathway, examination of the
expression levels of the CDK-inhibitors, p21WAF1 [13,40,41],
p27Kip1 [42,43] and p57Kip2 [19,44], which are responsible for
binding to and inhibiting the activity of the various cyclin–
CDK complexes and preventing transition through the cell cy-cle, was conducted (Fig. 4). In normal cells, DNA damage
causes cell-cycle arrest at the G1/S phase of the cell cycle via
p53 stimulation of p21WAF1 expression [13,45]. Noda et al.
[46] suggested that the highest level of p21WAF1 expression
was observed in senescent cells, which is in agreement with
our results (Fig. 4). Compared to primary passage 6 CEF cells,
passage 50 SC-1 cells showed a 30% increased level of
p21WAF1, which was signiﬁcantly less than the increased level
observed in senescent passage 18 CEF cells. The mRNA
expression levels of p21WAF1 were dramatically decreased at
passage 75, similar to levels found in DF-1 cells, but by pas-
sage 120, SC-1 cells expressed half as much p21WAF1 as did
primary passage 6 CEF cells. In a concomitant, albeit oppo-
site, manner with p53 expression, CHX treatment increased
the expression of p21WAF1 by 50% and 15% in passage 6
CEF and passage 120 SC-1 cells, respectively, compared to
untreated cells (Fig. 4). The coordinated ﬂuctuation observed
with p21WAF1 and p53 at various passages of the SC-1
cells was expected since p53 regulates the expression of
p21WAF1. This again supports the hypothesis that the cells
Fig. 5. Silencing of p53 by siRNA. (A) mRNA expression levels of p53
and p53-related genes before and after silencing of p53 using siRNA
directed against p53. (B) Growth rate analysis of normal and p53-
silenced SC-1 cells.
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until a fully immortal state was reached. However, the large
increase in p53 expression resulting from CHX treatment did
not translate into a large increase in p21WAF1 expression. This
can be explained by the ﬁnding that the increased p53 mRNA
expression following CHX treatment did not translate into
functional protein.
Unlike p21WAF1, the p27Kip1 protein is not inﬂuenced by p53
levels. Instead, its expression increases in response to extracel-
lular anti-proliferative signals, such as when normal cells are
grown to conﬂuence or in the absence of serum [47–49]. In
addition, levels of p27Kip1 mRNA were shown to be maximal
at senescence, and overexpression of p27Kip1 has been shown
to induce G1 cell-cycle arrest [50,51]. Plus, antisense p27Kip1
constructs have been shown to stimulate cell-cycle progression
[49]. In the present study, levels of p27Kip1 did indeed rise in
normal senescent CEF cells (Fig. 4) compared to levels in pas-
sage 6 CEF cells. In the SC-1 cell line, ﬂuctuation of p27Kip1
expression was observed with passages 50 and 120 having lev-
els comparable to normal senescent CEF cells while passage 75
expressed half these levels. This would seem to indicate that the
SC-1 cells were being limited in growth rate, in part, by the ac-
tions of p27Kip1. The lack of change in p27Kip1 expression in
SC-1 cells treated with CHX supports the hypothesis that lev-
els of p27Kip1 are not inﬂuenced by p53.
Initially, it was suggested that p57Kip2 was not regulated by
p53 [19], but more recent evidence suggests that p53 is neces-
sary for the expression of p57Kip2 [20]. Most immortal cell lines
do not express p57Kip2 mRNA [18]. Like other members of the
Kip/Cip family, overexpression of p57Kip2 arrests cells in the
G1 phase of the cell cycle [19]. In the present study the expres-
sion of p57Kip2 did increase at senescence. The expression lev-
els of p57Kip2 in passages 50 and 75 of the SC-1 cells were
elevated, similar to levels detected in the immortal DF-1 cells.
While these results do not agree with others who have found
that expression of p57Kip2 is decreased in immortal cells, by
passage 120 the levels of p57Kip2 mRNA expression were only
half of the levels observed in passage 6 primary CEF cells, indi-
cating that the SC-1 cells may be more similar to other immor-
tal cells that show decreased expression of p57Kip2 mRNA [18].
Treatment of passage 120 SC-1 cells with CHX increased the
expression of p57Kip2 2.5-fold, indicating that a putative inhib-
itory protein also may be present that suppresses the expres-
sion of p57Kip2 in later-passage SC-1 cells, allowing them to
progress to a fully immortal state.
3.4. Silencing of p53 by siRNA
Finally, to determine whether attenuation of p53 in early
passage SC-1 cells would accelerate the immortalization pro-
cess, small-interfering RNA (siRNA) directed against p53
(sip53) was transfected into passage 58 SC-1 cells. RT-PCR
analysis of p53 at passage 61 revealed that the sip53 construct
was successful in silencing of the p53 mRNA (Fig. 5A). How-
ever, the levels of mRNA expression of genes involved in the
p53 pathway did not change as predicted. MDM-2 mRNA
expression was unchanged by silencing of p53 in the SC-1 cells,
and while it was expected that expression of p21WAF1 should
have decreased in the p53-silenced cells, this was not the case.
Rather an increase in p21WAF1 (50%) and p57Kip2 (15%)
transcription was observed. Silencing of p53 did not increase
the growth rate of the early passage SC-1 cells (Fig. 5B) or
change the morphology to a more ﬁbroblastic population asthey remained ﬂattened and enlarged compared to later pas-
sage SC-1 cells and primary passage 6 CEF cells (data not
shown). It appears that other cell-cycle inhibitors including
p21WAF1 and p57Kip2 were subsequently elevated in p53-si-
lenced cells, preventing an increase in growth rate and acceler-
ation of the immortalization process.
3.5. Analysis of the Rb pathway
The retinoblastoma gene (Rb) is an important tumor sup-
pressor and its pathway plays an essential role in cellular reg-
ulation in many diﬀerent cell types. The importance of Rb
tumor suppressor activity was demonstrated by its forced
expression in Rb-deﬁcient tumor cells, which resulted in the
cessation of tumorigenic growth [52]. This agrees with a pre-
vious study that showed upregulated Rb expression in the
DF-1 cell line [29]. The current study demonstrated similar
results, as the SC-1 cells showed a ﬂuctuation in the expres-
sion of Rb, with mRNA levels lower at passages 50 and
75, but elevated in later passage cells compared to primary
passage 6 CEF cells (Fig. 6A). The upregulation of Rb in
the SC-1 cells may be the result of de-regulation, since others
have shown that Rb mRNA expression is repressed by p53 in
mammalian cells [17].
The expression of p16INK4a was examined next since genetic
alterations involving p16INK4a are second only to the p53 alter-
ations observed for human cancers [22,23,53,54]. It recently
has been discovered that chickens do not contain a p16INK4a
orthologue. They do, however, encode p15INK4b, which likely
assumes the role of p16INK4a [55]. In the present study, the
mRNA expression levels of p15INK4b were measured and, as
Fig. 6. (A) Levels of mRNA expression for genes involved in the Rb/p16INK4a pathway. (B) Restoration of p15INK4b mRNA expression in DF-1 and
SC-1 cells using the DNA methylation inhibitor 5 0-aza-2 0-deoxycytidine. For each gene analyzed, the expression level was set to 1.00 for passage 6
CEF cells. The levels for other samples were then adjusted accordingly. A minimum of three independent RT-PCR experiments were analyzed using
the NIH image software program and normalized using the expression levels of GAPDH. Diﬀerences60.05 were considered signiﬁcant. (C) p15INK4b
protein levels in primary passage 6 CEF, passage 50 SC-1, passage 120 SC-1, and immortal DF-1 cells. A minimum of three independent Western
blot experiments were analyzed using the NIH image software program and normalized using the expression levels of actin. Diﬀerences 60.05 were
considered signiﬁcant. (D) Levels of mRNA expression for the various cyclin genes. For each gene analyzed, the expression level was set to 1.00 for
passage 6 CEF cells. The levels for other samples were then adjusted accordingly. A minimum of three independent RT-PCR experiments were
analyzed using the NIH image software program and normalized using the expression levels of GAPDH. Diﬀerences 60.05 were considered
signiﬁcant.
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agrees with data showing that levels of p16INK4a accumulated
in normal primary mouse and human cells undergoing senes-
cence [56]). The levels of p15INK4b in all passages of SC-1 cells
and in the immortal DF-1 cells were undetectable by RT-PCR.
These results are similar to those obtained by others who have
reported that p16INK4a is inactivated in many human tumors
and transformed cell lines [23]. The levels of p15INK4b were re-
stored using the DNA methylation inhibitor 5 0-aza-2 0-deoxy-
cytidine in SC-1 and DF-1 cells (Fig. 6B), suggesting that the
downregulation of p15INK4b was due to promoter hypermethy-
lation. This result is supported by the fact that transcriptional
silencing of p16INK4a in many immortal cells is due to hyper-
methylation of its promoter [57]. Additionally, protein levels
of p15INK4b were undetectable in all passages of SC-1 and
DF-1 cells that were analyzed (Fig. 6C).In addition to p16INK4a, the p16INK4a ARF sequence pro-
tein, which is encoded by the same genetic locus as p16INK4a,
but in a diﬀerent reading frame, plays an important role in tu-
mor suppression. ARF functions upstream of MDM-2 and
p53 by stably binding to MDM-2, thus preventing MDM-2
from exporting p53 to the cytoplasm for degradation [58–
60]. In fact, it has been reported that ARF is required for
senescence, and is inactivated in many human tumors [27].
As expected, increased expression of ARF was observed in
normal senescent CEF cells (Fig. 6A). In the SC-1 cells, a ﬂuc-
tuation in ARF expression was seen, with lower levels of ARF
observed in SC-1 cells at passages 50 and 75. However, by pas-
sage 120, levels of ARF increased to those observed in normal
senescent CEF and immortal DF-1 cells. The fact that ARF
mRNA levels were elevated in passage 120 SC-1 and immortal
DF-1 cells can be resolved by the fact that these cells possessed
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the levels of p21WAF1 and MDM-2.
The E2F-1 transcription factor, a regulatory member of the
Rb/p16INK4a pathway is required for the transition of the G1
to S phase of the cell cycle. The E2F-1 protein is bound to hyp-
ophosphorylated Rb, and upon phosphorylation, Rb releases
E2F-1, and cells are then able pass from G1 into the S phase
of the cell cycle. E2F-1 has been shown to be downregulated
in senescent human cells [61] and in senescent CEF cells (as ob-
served in Fig. 6A). The levels of E2F-1 in SC-1 cells ﬂuctuated
from a slight increase at passage 50 to a slight decrease at pas-
sage 75 to a dramatic 150% increase at passage 120 compared
to primary passage 6 CEF cells. The deregulation of the E2Fs,
including E2F-1, is a hallmark of human cancers [22], and pre-
vious work in our laboratory has shown that mRNA, protein,
and functional activity of E2F-1 were dramatically elevated in
all immortal cells studied [29]. The E2F-1 data from the SC-1
cells suggests that important cell-cycle regulatory genes are
modulating their expression until reaching steady-state levels
similar to those observed in other immortal cell lines. Taken
together, the expression levels of p16INK4a and E2F-1 indicate
that the Rb/p16INK4a pathway was altered in the SC-1 cell line.
Also, the elevated levels of ARF also may be attributed to the
elevated levels of E2F-1 that were observed in the passage 120
SC-1 cells, since it has been shown that E2F-1 stimulates
expression of ARF [62].3.6. Expression analysis of various cell-cycle regulatory genes
The various cyclins were examined due to their importance
in regulating cell-cycle events [22] (Fig. 6D). In normal CEF
cells, expression of cyclins A, B2, B3, C, D1, and E decreased
between 10% and 100% at senescence, while the expression of
cyclin D2 was slightly increased compared to primary passage
6 CEF cells. In SC-1 cells, the mRNA expression levels of most
of the cyclins were decreased somewhat at passage 50, but dra-
matically decreased (33–100%) by passage 75. However, by
passage 120, cyclin mRNA levels had modulated with cyclins
B2, C, D2, and E decreased by 10–55%, while cyclin B3 was
increased by 43%. The levels of cyclins A and D1 were similar
to levels found in primary passage 6 CEF cells. The immortal
DF-1 cell line showed between a 25% and 100% decrease in
expression of cyclins B2, B3, C, D1, D2, and E, compared to
primary passage 6 CEF cells, while levels of cyclin A were sim-
ilar to levels observed in primary passage 6 CEF cells. Other
studies have shown a downregulation of the cyclin genes in
quiescent cells [63–66]. An exception is cyclin D2, which has
been shown to increase expression in growth-arrested cells
[67]. In addition, numerous studies have shown that the upreg-
ulation of the various cyclins promotes cell-cycle progression,
as in immortal cells [64,68–70].3.7. Telomere regulation
Generally, telomerase activation has been shown to be an
important step in the immortalization of normal ﬁbroblasts
[71]. However, telomerase expression in the DF-1 cell line (as
well as all other immortal CEF cell lines) which, by all other
indicators appears to be fully immortal, has never been demon-
strated. Although telomerase activity was undetectable in the
SC-1 cells, telomere length did not decrease, even in senescent
passage 18 CEF or immortal cells (data not shown). This indi-
cates that alterations in the p53 and Rb pathways may be moreimportant than telomerase activation for the initial events
leading to the immortalization of CEF cells, as well as for
the maintenance of that phenotype. It is possible that these
immortal CEF cells may have very low levels of telomerase
activity that are undetectable using the TRAP assay, but suﬃ-
cient for maintenance of telomere length. Alternatively, telo-
mere length may be maintained through diﬀerent
mechanisms, as has been proposed in a variety of human cell
lines that do not show telomerase activity [72,73]. Levels of
TRF-2 were measured since it has been reported that TRF-2
is involved in the maintenance of telomeres [74]. It is possible
that the slightly elevated levels of TRF-2 found in passage 120
SC-1 cells may have participated in the stabilization of the
telomere length (data not shown).
In conclusion, we report the establishment of a spontane-
ously immortalized CEF cell line. Unlike the spontaneously
immortalized DF-1 cell line, the protein and mRNA expres-
sion levels of numerous genes have been analyzed in the SC-
1 cell line at various passages during the conversion to an
immortal state. It is possible that the SC-1 cell line may be a
better model of normal growth in chicken cells. Although both
the SC-1 and DF-1 cells possess a normal karyotype, the
growth rate of the SC-1 cells is more similar to normal primary
CEF cells than is the DF-1 spontaneously immortalized CEF
cell line. The SC-1 cells may allow for a better understanding
of the necessary changes that are required for the complete
immortalization process in ﬁbroblast cells. It appears that
the SC-1 cells may have traversed one or more transition or
crisis periods, whereby the levels of p53 and p53-regulated
genes were diﬀerentially regulated, allowing the cells to convert
from a life-span-extended population of cells into a more fully
immortalized cell line. The decrease in the expression of
p57Kip2 mRNA by passage 120 in the SC-1 cells indicates that
they may be converting to a fully immortal phenotype. It is
possible that alterations in other p53-related genes may be nec-
essary for the attainment of full immortality in the SC-1 cells.
Our results indicated that the loss of p15INK4b may be neces-
sary for SC-1 cells to initially overcome the regulated con-
straints imposed upon senescent cells.
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